Overview

Rituximab in Metastatic Melanoma

Status:
Terminated

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether rituximab as an adjuvant therapy in clinical stage IIIc / IV (no evidence of disease, AJCC (American Joint Committee on Cancer) 2002) melanoma patients is safe and prolongs overall survival and disease-free interval.

Phase:

Phase 1

Details

Lead Sponsor:

Medical University of Vienna

Treatments:

Rituximab